A first-of-its kind value deal between Illumina Inc. and Harvard Pilgrim Health Care Inc. is intended to generate data to support broad reimbursement by multiple payers for non-invasive prenatal tests made by multiple testing companies.
read full article ›Biopharma is not moving as quickly in 2018 as its counterparts in adjacent industry segments, and is confronting a strategic dilemma on how to address the prospect of a much more powerful set of rivals in the ongoing battle to own the patient experience in medicine.
read full article ›Labeling for reduction of cardiovascular risk may help a bit with payers, but the "twin problem" of pricing and lack of patient adherence is likely to continue to present hurdles for reimbursement.
read full article ›In the past, organizations working in different pockets of the health sector made decisions according to their own business priorities. But as pharmaceutical and life sciences pipelines rebound, consumer choice and provider cost-savings incentives are driving change in the industry’s commercial model. As US specialty drug spending hits an all-time high, purchasers, prescribers and patients are considering price as a key component of a drug’s expected health benefit.
read full article ›Two of the biggest pharmaceutical companies in the world did something unusual this week when they announced the introduction of breakthrough drugs: they charged less.
read full article ›The maturation of the biotech sector over the past few years finds fund managers focusing on a slew of clinical milestones and commercial launches in 2015, but only a handful of approvals.
read full article ›That Apple ($APPL) watch you are wearing may allow you to text and listen to music, and it can track your activity. But it may also be conducting a postmarket study that will help cut the price of some of your prescription drugs in the future.
read full article ›Gilead Sciences Inc. and AbbVie Inc. continue to vie for preferred coverage of their HCV drugs in the U.S. private payer market, and Gilead is out to an early lead when it comes to total lives covered. But much of the population is still up for grabs, and the real victor in share of lives could be determined by how the U.S. Department of Veterans Affairs and Medicaid plans respond.
read full article ›How Sanofi should think about pricing/rebates for first-to-market PCSK9 inhibitor
read full article ›Hepatitis C drugs may have provided the spark, but cost-pressured payors, empowered consumers, and at-risk providers are adding fuel to the drug pricing fire. The game may be up for pharma firms that try to push prices out of line with perceived value, potential patient volumes, and affordability.
read full article ›